Theravance Biopharma, Inc.
TBPH
$17.06
-$0.01-0.03%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -20.86% | 15.02% | 144.70% | 18.51% | 83.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.86% | 15.02% | 144.70% | 18.51% | 83.75% |
| Cost of Revenue | -55.08% | -49.10% | -22.14% | -12.47% | 5.38% |
| Gross Profit | 2.00% | 201.58% | 314.27% | 56.29% | 265.06% |
| SG&A Expenses | -23.08% | -3.54% | 0.10% | 8.64% | 8.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.69% | -21.03% | -7.42% | 1.16% | 7.07% |
| Operating Income | 167.63% | 59.47% | 317.51% | 30.40% | 78.63% |
| Income Before Tax | -106.54% | 54.24% | 917.41% | 71.26% | 580.95% |
| Income Tax Expenses | -93.97% | -174.96% | 82.82% | -345.80% | 1,304.51% |
| Earnings from Continuing Operations | -110.76% | 63.67% | 493.02% | 128.47% | 431.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -110.76% | 63.67% | 493.02% | 128.47% | 431.75% |
| EBIT | 167.63% | 59.47% | 317.51% | 30.40% | 78.63% |
| EBITDA | 195.42% | 60.99% | 332.51% | 31.61% | 81.21% |
| EPS Basic | -110.45% | 64.79% | 480.98% | 127.66% | 422.26% |
| Normalized Basic EPS | -92.93% | 80.54% | -464.70% | 67.01% | 679.66% |
| EPS Diluted | -110.57% | 64.79% | 466.59% | 126.92% | 417.65% |
| Normalized Diluted EPS | -92.85% | 80.54% | -441.39% | 67.84% | 673.43% |
| Average Basic Shares Outstanding | 2.97% | 3.16% | 3.17% | 3.02% | 2.93% |
| Average Diluted Shares Outstanding | 1.86% | 3.16% | 7.60% | 5.85% | 4.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |